Kbc Group Nv Hutchmed (China) LTD Transaction History

Kbc Group Nv

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$15.52 - $35.65 $278,708 - $640,202	-17,958 Closed	0 $0
Q4 2021 Feb 14, 2024	BUY	$28.89 - $35.33 $518,806 - $634,456	17,958 New	17,958 $630,000
Q4 2021 Feb 03, 2022	BUY	$28.89 - $35.33 $370,456 - $453,036	12,823 Added 249.72%	17,958 $630,000
Q3 2021 Nov 10, 2021	BUY	$35.66 - $42.94 $183,114 - $220,496	5,135 New	5,135 $188,000
Q1 2020 May 04, 2020	SELL	$15.19 - $29.51 $30,045 - $58,370	-1,978 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$21.27 - $30.58 $42,072 - $60,487	1,978 New	1,978 $0

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.22B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.